StockNews.AI
VYGR
StockNews.AI
176 days

VOYAGER ALERT: Bragar Eagel & Squire, P.C. is Investigating Voyager Therapeutics, Inc. on Behalf of Voyager Stockholders and Encourages Investors to Contact the Firm

1. Law firm investigates VYGR for potential securities law violations. Claims alleged misconduct. 2. Voyager denies IND filing for VY9323 due to off-target effects. Preclinical data unmet standards. 3. Gene therapy program shift raises doubts on payload's efficacy. Concerns impact therapeutic progress. 4. News resulted in a 20.86% stock price drop. Immediate market reaction evident.

4m saved
Insight
Article

FAQ

Why Bearish?

The article details legal investigations and clinical setbacks that directly impacted VYGR's stock price by over 20%, echoing historical cases where similar negative news led to investor sell-offs in biotech companies.

How important is it?

The combination of legal action and significant clinical program issues directly affecting investor confidence makes this news highly important for VYGR.

Why Short Term?

The immediate drop and pending litigation suggest a short-term price impact; however, longer-term effects remain uncertain until legal outcomes are known.

Related Companies

CRSPEDITBIIB
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Voyager Therapeutics, Inc. (“Voyager” or the “Company”) (NASDAQ:VYGR) on behalf of Voyager stockholders. Our investigation concerns whether Voyager has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On February 11, 2025, Voyager issued a press release "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed therapeutic window." Voyager further stated that it "no longer anticipates filing an investigational new drug (IND) application for VY9323 in mid-2025." On this new, Voyager's stock price fell $1.11 per share, or 20.86%, to close at $4.21 per share on February 11, 2025. If you purchased or otherwise acquired Voyager shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, by telephone at (212) 355-4648, or by filling out this contact form.  There is no cost or obligation to you. About Bragar Eagel & Squire, P.C.: Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information: Bragar Eagel & Squire, P.C.Brandon Walker, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com

Related News